Edible and food safe cryopreservation systems
The use of an egg yolk-based cryopreservation medium with edible cryoprotectants addresses the cost and safety issues of existing methods, achieving high cell viability and safety for consumption in cellular agriculture applications.
Patent Information
- Application Number
- PCT/US2024/030498
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
Current cryopreservation methods in cellular agriculture are unsuitable due to the use of harmful chemicals and high costs, necessitating the development of edible and food-safe cryopreservation systems.
A cryopreservation medium comprising egg yolk and additional edible cryoprotectants such as glycerin, sorbitol, and trehalose, which does not include dimethyl sulfoxide, is used to effectively preserve non-human animal cells, offering a cost-effective and safe solution for cellular agriculture applications.
The proposed medium achieves a recovery survival rate of at least 50% and preferably 70% of cells post-thawing, making it feasible for large-scale cryopreservation in cellular agriculture, while being safe for human and animal consumption.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
Attorney Docket No.121430-791898 EDIBLE AND FOOD SAFE CRYOPRESERVATION SYSTEMS CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No.63 / 468,459 filed May 23, 2023, which is incorporated by reference herein in its entirety. BACKGROUND
[0002] 1. Field
[0003] The present invention relates to edible and food safe compositions and methods for cryopreservation for cellular agriculture applications. Use of the disclosed compositions in the field of cellular agriculture and other related fields is provided.
[0004] 2. Background
[0005] Currently, factory farming is the primary way for production of most animal products all around the world, but especially in the United States of America. However, factory farming is rife with ethical and environmental issues, especially since global demands have increased dramatically. In the recent years, the meat industry is moving away from factory farming and towards products that mimic animal products, for instance plant-based meat. However, it is hard to achieve the texture, flavor, and nutritional benefits of meat from such products.
[0006] Cultured meat, or cell-based meat, is meat that is produced using cellular agriculture techniques using in vitro cell culture or bioreactor systems, instead of being harvested from live animals. Cultured meat produced from cell cultures provides a viable alternative to address concerns about factory farming without having to turn to a completely vegetarian or vegan diet. Assessments have shown that cultured meat has the capacity to significantly reduce land and water use, emit fewer greenhouse gases, and reduce agriculture-related pollution and eutrophication. It also provides a more ethical way of producing food, avoiding animal confinement, mistreatment of animals and animal slaughter. In particular, cultured meat can be obtained from animal-based components, but with the advantage of sustainably increased yields, similarity of underlying structure and nutrition to factory farmed animals. In addition, cultured animal cells can also be used for production of other animal products like leather, horns, or feathers. Industrialized animal cell culture has also proven to be useful for medical purposes, for example for production of recombinant proteins, tissues, organs and organoids. 1 95004041.1Attorney Docket No.121430-791898
[0007] Cryopreservation methods are key to any successful cellular agriculture enterprise. Cryopreservation can be used at several key operational points in the system, for example for storage of cells and cell lines for consistent product production. Cryopreservation is also useful during bioreactor operations and cell culture stage because systems can be unreliable, and batch freezing may be required at any step during the process to prevent wastage. Cryopreservation is also necessary to ensure proper storage and transport of the final product. However, currently available cryopreservation methods use harmful chemicals or have high costs that make them unsuitable for use in cellular agriculture. There is therefore an unmet need in the field for efficient Cryopreservatives and cryopreservation methods that use edible and food safe ingredients and are cost effective. SUMMARY OF THE INVENTION
[0008] In some aspects the current disclosure encompasses a cryopreservation medium for use in cellular agriculture applications, the medium comprising egg yolk and at least one additional edible cryoprotectant. Non-limiting examples of edible cryoprotectants include glycerin, sorbitol, trehalose, polyvinylpyrrolidone(PVP), betaine, carboxylated poly-l-lysine, glucose, dextran, proline, peptides, sucrose or any combination thereof. In some aspects, the cryoprotection medium does not contain dimethyl sulfoxide (DMSO).
[0009] In some aspects, the cryoprotection medium comprises about 5% to about 30% of egg yolk. In some aspects, the cryoprotection medium comprises about 20% of egg yolk. In some aspects, the cryoprotection medium comprises about 5% to about 25% glycerin. In some aspects, the cryoprotection medium comprises about 10% glycerin. In some aspects, the cryoprotection medium comprises egg yolk obtained from an oviparous animal, non-limiting examples of which include fish, amphibian, reptile, or any combination thereof. In some aspects, the egg yolk is from an avian animal, for example a chicken, ostrich, quail, partridge, turkey etc.
[0010] In some aspects, the medium further comprises one or more of a salt, a sugar, a fat, a basal medium, a growth factors, amino acids, vitamins, minerals, edible surfactants, preservatives, antibiotics, pectin, alginate, agarose, elastin, chitin, chitosan, fibrin, fibrinogen, polysaccharides, alginates, collagen, gelatin, poly(amino acids), peptides, polypeptides, fibers, buffering agents, or any combinations thereof.
[0011] In some aspects, the medium is for the cryopreservation of at least one non-human cell. In some aspects, the medium is for cryopreservation of a population of non-human animal cells, non-human cell lines, non-human cell population, non-human cell cultures, non-human tissue, non-human organ or non-human cellular biomass. 2 95004041.1Attorney Docket No.121430-791898
[0012] In some aspects, the non-human animal cell is a fibroblast, a myoblast, an adipocyte, a stem cell, an endothelial cell, or a mesodermal cell or any combination thereof. In some aspects, the non-human cell cultures, or non-human cellular biomass is preserved in a bioreactor container. In some aspects, the temperature range of the cryopreservation is −20° C. to −196° C.
[0013] In some aspects, the medium is a ready-to-use medium. In some aspects, the medium is a concentrate. In some aspects, the current disclosure also encompasses a method of cryopreservation for cellular agriculture applications, the method comprising contacting at least one non-human animal cell with a medium comprising egg yolk and at least one additional edible cryoprotectant.
[0014] In some aspects, the current disclosure also encompasses a method of cryopreservation for cellular agriculture applications, the method comprising contacting at least one non-human animal cell with the cryopreservation medium as disclosed herein. In some aspects, the non- human animal cell is a fibroblast, a myoblast, an adipocyte, a stem cell, an endothelial cell, or a mesodermal cell or any combination thereof. In some aspects, the at least one non-human cell is part of a non-human cell population, non-human cell cultures, non-human tissue, non-human organ, non-human cellular biomass, or non-human cell grown on microcarrier and / or scaffolds. In some aspects, the non-human cell may be in any vessel, for example a dish, tube, plate, jar or a bioreactor.
[0015] In some aspects, the recovery survival rate of the non-human cell after cryopreservation is at least 50% and preferably 70% or more.
[0016] In some aspects of the disclosed method, the non-human cells are suspended in the cryopreservation medium at a concentration that 1×102to 1×109non-human cells / mL of said cell cryopreservation protective solution. In some aspects, the temperature range of the cryopreservation is −20° C. to −196° C. In some aspects, the cryopreservation is ultrarapid cryopreservation. In some aspects, the cryopreservation is gradual cryopreservation.
[0017] In some aspects, the current disclosure also encompasses a method of cellular agriculture, the method comprising; a) growing non-human animal cells in a bioreactor container; b) adding a cryopreservation medium as disclosed herein to the bioreactor container; c) freezing the non-human animal cells in the bioreactor container. In some aspects, step (c) uses ultrarapid freezing. In some aspects, the non-human animal cells are grown to a density of about 1×102to 1×109non-human cells / mL. In some aspects, the recovery survival rate of the non-human animal cells is at 50% and preferably 70% or more. In some aspects, the method further comprises 3 95004041.1Attorney Docket No.121430-791898 thawing the non-human animal cells in the bioreactor container. In some aspects, the method further comprises resuming the growth of the non-human cells. In some aspects, prior to freezing, the cells are concentrated using a filtration or centrifugation method. In some aspects, the cells are for production of a cultured meat product. In some aspects, the method is used for production of cultured meat products, recombinant proteins, or structured animal products. DETAILED DESCRIPTION
[0018] The following detailed description illustrates various aspects of the present disclosure. The description is intended to describe aspects of the present disclosure in sufficient detail to enable those skilled in the art to practice the present inventive concept. Other components can be utilized, and changes can be made without departing from the scope of the present inventive concept. The following description is, therefore, not to be taken in a limiting sense. The scope of the present inventive concept is defined only by the appended claims, along with the full scope of equivalents to which such claims are entitled.
[0019] The present disclosure is based, in part, on the discovery that media comprising egg- yolk is an efficient cryopreservative. Traditionally, cell preservation is done using media that contain dimethyl sulfoxide or similar chemicals that can be harmful for human and animal consumption. These chemicals need to be removed before the products can be consumed. This makes the process of cryopreservation unnecessarily cumbersome and costly and may pose unknown risks to humans if consumed over long periods. Edible preservatives like salts and sugars add unwanted flavor and change food texture, thus making them unsuitable for cellular agriculture type applications. The current disclosure provides cryopreservatives compositions comprising egg yolk and at least one other edible cryoprotectant, the combination of which makes large scale cryopreservation feasible. Egg yolks are naturally resistant to low temperature fluctuations as would be experienced by an embryo in the wild and function as membrane protectors. Additionally, eggs are inexpensive, easily available, and easy to manipulate thus making them desirable additives to food formulations. However, thus far egg-based cryopreservatives have not been used in cellular agriculture application. Other applications that use egg yolks as cryopreservatives usually depend on eggs to provide membrane protection, while other components like DMSO are used to maintain internal structure and viability after freezing. In some aspects, the composition and methods disclosed herein, do not use DMSO. In some aspects, the compositions and methods disclosed herein use egg yolk as the primary cryopreservative. 4 95004041.1Attorney Docket No.121430-791898 I. Composition In some aspects, the current disclosure encompasses compositions comprising egg yolks and at least one additional edible cryoprotectant, for cryopreservation in applications related to cellular agriculture. As used herein, the term “cellular agriculture” refers to the field of growing animal agricultural products directly from cell cultures instead of using poultry and livestock farming. When used herein “egg yolk” or “deutoplasm” refers to the nutrient-bearing portion of the egg whose primary function is to supply food for the development of the embryo. Egg yolks can be uniformly distributed in an egg, as in isolecithal or homolecithal eggs of invertebrates, or concentrated in one hemisphere of the egg, as in telolecithal eggs or may be centrally placed as in centrolecithal eggs. In some aspects, the egg yolk is rich in fatty acids, vitamins, proteins and minerals. Egg yolks are usually separated from the surrounding portion of an egg by a vitelline membrane.
[0021] In some aspects, compositions of the current disclosure may comprise egg yolks from any oviparous animal including but not limited to fish, amphibians, reptiles or birds. In some aspects, the egg is a bird egg. Non-limiting examples of birds from which the egg protein may be derived include chicken, duck, emu, goose, guinea fowl, gull, ostrich, pheasant, pigeon, quail, and turkey. In some aspects, the egg is a fish egg. Non-limiting examples include eggs from fishes that are used as common sources of tobiko, masago, ikura, or caviar for example salmon, paddlefish, bowfin, whitefish, trout, capelin or flying fish, bottarga, lumpfish etc. In some aspects, the egg maybe a reptile egg for example a crocodile, alligator, snake, or lizard egg. In some aspects, the egg yolk as disclosed herein may be isolated from a fertilized or an unfertilized egg. In some aspects, the egg yolk may be isolated from a fertilized egg. In some aspects, the egg yolk may be isolated from a fertilized egg in the first trimester. In some aspects, the egg yolk may be from a naturally occurring or recombinant animal. In some aspects, the egg yolk may be produced in vivo or in vitro.
[0022] In some aspects, the compositions of the current disclosure comprise at least one additional edible and food safe cryoprotectant. Non-limiting examples of cryoprotectants that can be combined with egg yolks in the current disclosure include glycerin, sorbitol, trehalose, sucrose, PVP, betaine, carboxylated poly-l-lysine, glucose, dextran, peptide cryoprotectants or proline. In some aspects, the additional cryoprotectant for use in compositions disclosed herein is not dimethyl sulfoxide (DMSO).
[0023] In some aspects, the compositions as disclosed herein may comprise about 5% to about 30% egg yolk by weight of the composition. In some aspects, the composition comprises about 5 95004041.1Attorney Docket No.121430-791898 1% to about 5% or about 5% to about 10%, or about 10% to about 15%, or about 15% to about 20%, or about 20% to about 25%, or about 25% to about 30% egg yolk by weight of the composition. In some aspects, the composition comprises about 20% of egg yolk. In some aspects, the compositions disclosed herein may comprise at least one additional cryoprotectant as disclosed above. In some aspects, the compositions comprise about 1% to about 5%, or about 5% to about 10%, or about 10% to about 15%, or about 15% to about 20%, or about 20% to about 25% by weight of the edible cryoprotectant disclosed herein. In some aspects, the edible cryopreservative is glycerin. In some aspects, the composition comprises about 1% to about 5%, or about 5% to about 10%, or about 10% to about 15%, or about 15% to about 20%, or about 20% to about 25% of glycerin by weight. In some aspects, the composition comprises about 10%, about 11%, about 12%, about 13%, about 14% or about 15% of glycerin. In some aspects, the composition comprises 12% glycerin.
[0024] In some aspects, the cryopreservation medium as disclosed herein may further comprise one or more additional ingredients including but not limited to a salt, a sugar, a fat, a basal medium, a growth factors, amino acids, vitamins, minerals, edible surfactants, preservatives, antibiotics, pectin, alginate, agarose, elastin, chitin, chitosan, fibrin, fibrinogen, polysaccharides, alginates, collagen, gelatin, poly(amino acids), peptides, polypeptides, fibers, buffering agents or any combinations thereof. In some aspects, each of the one or more additives may be included at about 0.001% to about 10% by weight of the composition. In some aspects, each of the one or more additives may be included at about 0.001% to about 0.01%, 0.01% to about 0.05%, 0.05% to about 0.1%, 0.1% to about 0.5%, 0.5% to about 1%, 1% to about 5%, or 5% to about 10% by weight of the composition.
[0025] In some aspects, the cryopreservation media composition as disclosed herein may be formulated as a ready-to-use formulation such that it can be added directly to the sample to be cryopreserved. In some aspects, the cryopreservation medium may be formulated as a concentrate that is diluted with the culture medium, cell culture or water, depending on application and the exact composition of the cryopreservation media. In some aspects, the concentrate may be anywhere between a 2 X to a 100 X concentrate. Methods for concentrating media components are well known in the art and may comprise for example, lyophilization, freeze drying, spray drying micro or nanofiltration steps. In some aspects, the compositions disclosed herein may also be formulated as powder or pastes to be added to the culture medium as desired.
[0026] In some aspects, the compositions of the current disclosure may be formulated to work at different temperature ranges and for different applications. For example, in some aspects, the 6 95004041.1Attorney Docket No.121430-791898 relative ratios of egg yolk to the edible cryoprotectants may be varied depending on the desired temperature for freezing. In some aspects, the composition is formulated to be protective when a sample is frozen and stored at a temperature range of about −20° C to −196° C. In some aspects, the composition is protective when a sample is frozen and stored at a temperature range of about −20° C to about −40° C, or about −40° C to about −60° C, or about −60° C to about −80° C, or about −80° C to about −100° C, or about −100° C to about −120° C, or about −120° C to about −140° C. or about −140° C to about −160° C, or about −160° C to about −180° C, or about −180° C to about −200° C. As such the ratio of the egg yolk to the edible cryoprotectant may vary from about 0.01:1 to about 5:1, for example 0.01:1, or 0.5:1, or 1:1, or 2:1, or 3:1, or 4:1, or 5:1.
[0027] In some aspects, the disclosed compositions may be formulated for use at any stage, and any system of cellular agriculture. In some aspects, the compositions, as disclosed herein may be formulated for preservation of non-human cells, cell lines, cell populations, tissues, organs, organoids, or cellular biomass. Any type of cell may be preserved using the formulations disclosed herein, including fibroblast, a myoblast, an adipocyte, a stem cell, an endothelial cell, or a mesodermal cell or any combination thereof. In some aspects, the disclosed compositions may be added directly to a bioreactor for preserving biomass. In some aspects, the ratio of the egg yolk to the edible cryoprotectant can be varied depending on the sample type, for example cells, tissues, biomass, organs, to maximize cryopreservation. As such the ratio of the egg yolk to the edible cryoprotectant may vary from about 0.01:1 to about 5:1, for example 0.01:1, or 0.5:1, or 1:1, or 2:1, or 3:1, or 4:1, or 5:1.
[0028] Details of the various applications and stages of cellular agriculture where these compositions can be used are provided in the methods section below. II. Methods
[0029] In some aspects, the current disclosure encompasses a method of cryopreservation for cellular agriculture applications, the method comprising contacting at least one non-human animal cell with a medium comprising egg yolk and at least one additional edible cryoprotectant. In some aspects, the current disclosure encompasses a method of cryopreservation for cellular agriculture applications, the method comprising contacting at least one non-human animal cell with a composition has provided herein.
[0030] In some aspects, the current disclosure encompasses the use of the compositions as disclosed herein for cryopreservation of non-human animal cells. As used herein, the term “non- human cell” encompasses any cell from a non-human source or a part thereof (tissue, organ, 7 95004041.1Attorney Docket No.121430-791898 system or embryo). As used herein, the term “derivative” of a non-human cell encompasses isolated cells, cell lines, or recombinant cell lines. In some aspects, the cell is an embryonic cell. In some aspects, the cell is a somatic cell. In some aspects, the cell is a differentiated cell. In some aspects, the cell is an adherent cell, for example a fibroblast, a myoblast, an adipocyte, an endothelial cell, or a mesodermal cell. In some aspects, the cell is a stem cell for example an embryonic stem cell, bone marrow derived stem cell, adipose derived stem cell, or induced pluripotent stem cell. In some aspects, the non-human cell is a vertebrate cell. Non-limiting examples of vertebrate cell suitable for use in the current disclosure include cells derived from fish, bird, amphibian, reptile, or mammals or recombinant cell lines thereof. In some aspects, the non-human cell is an invertebrate cell. Non-limiting examples of invertebrate cells suitable for the current disclosure include cells derived from oysters, mussels, clams, scallop, jelly fishes, squids, prawns, octopus, sea cucumbers, sea squirts or recombinant cell lines thereof. In some aspects, the current disclosure encompasses, obtaining a non-human animal cell, and cryopreserving it using the compositions disclosed herein, for future use in a cellular agriculture related application. In some aspects, the process requires addition for the cryopreservation media as disclosed herein to an adherent cell culture. In some aspects, the process requires mixing of the cryopreservation medium with a cell suspension at a desired concentration. The concentration of the cryopreservation medium can vary based on the various factors, like the composition of the suspension medium in which the cells are present. In some aspects, the exact formulation and concentration of the medium to be used for cryopreservation can be easily determined by a person of ordinary skill in the art, either empirically or based on manufacturer’s instructions.
[0031] In some aspects, the current disclosure encompasses cryopreservation of cells, wherein the non-human animal cells are suspended in the cryopreservation medium at a concentration that 1×102to 1×109non-human cells / mL. In some aspects, the concentration of cells in the cryopreservation compositions disclosed herein may vary from about 1×102to about 1×103, about 1×103to about 1×104, about 1×104to about 1×105, about 1×105to about 1×106, about 1×106to about 1×107, about 1×107to about 1×108, or about 1×108to about 1×109non-human cells / mL.
[0032] In some aspects, the compositions of the current disclosure can also be used cryopreserve the middle or end-product of a cellular agriculture process. For example, in some aspects, the compositions as disclosed herein may be used to cryopreserve a population of non- human animal cells, non-human tissue, non-human organ, non-human organoids, non-human cellular biomass, or non-human cell grown on microcarrier or scaffold. In some aspects, the composition can be used to preserve a population of non-human animal cells. In some aspects, 8 95004041.1Attorney Docket No.121430-791898 such a population of cells may be present in an adherent or a suspension culture or a combination thereof. In some aspects, the population of cells is a homogenous population. In some aspects, the population of cells is a heterogenous population. In some aspects, the population of cells is derived directly from an animal. In some aspects, the population of cells is a result of a cell culture process. In some aspects, the cell population is frozen in the culture medium supplemented with a composition as disclosed herein, for the purpose of cryopreservation. In some aspects, the culture medium comprise any medium known in the art. Non-limiting exemplary cell culture media that may be purchased from commercial vendors (e.g., Gibco, Sartorius, etc.), or synthesized, include SAFC Excell media, BME (basal Eagle Medium), MEM (minimum Eagle Medium), medium 199, DMEM (Dulbecco's modified Eagle Medium), GMEM (Glasgow modified Eagle medium), DMEM-HamF12, Ham-F12 (Gibco) and Ham-F10 (Gibco), IMDM (Iscove's Modified Dulbecco's medium), MacCoy's 5A medium, RPMI 1640, and GTM3. In some aspects, the cell population may be cryopreserved and stored in a dish, tube, plate, jar or a bioreactor.
[0033] In some aspects, the cell population is separated from the cell culture medium, for example using a technique like filtration, centrifugation, and then resuspended in the cryopreservation medium. In some aspects, the population of cells are cultured in a bioreactor and frozen within the bioreactor without concentration or removal of media. In some aspects, the cryopreservation medium as disclosed herein may be added directly to the bioreactor comprising the cell culture. In some aspects, these measures make it possible to halt cell culture operations at any stage in a cellular agriculture system. In the process of production of cultivated meat, it is necessary to freeze / stop the production because of accidental interruption in processing line. The ability to freezing large amount of cellular biomass could greatly save time and resource. Thus, in some aspects, the current disclosure also encompasses a method of cellular agriculture, the method comprising; a) growing non-human animal cells in a bioreactor container; b) adding a cryopreservation medium as disclosed herein to the bioreactor container; c) freezing the non- human animal cells in the bioreactor container. In some aspects, step (c) is an ultrarapid freezing. In some aspects, the non-human animal cells are grown to a density of about 1×102to 1×109non- human cells / mL. In some aspects, the recovery survival rate of the non-human animal cells is at least 50% and preferably 70% or more. In some aspects, the method further comprises thawing the non-human animal cells in the bioreactor container. In some aspects, the method further comprises resuming the growth of the non-human cells. In some aspect, the cryopreservation can be used for shipping large amounts of cellular biomass from one facility to another facility for further cultivation. 9 95004041.1Attorney Docket No.121430-791898
[0034] In some aspects, the current compositions can also be used to cryopreserve adherent cell populations, on plates, scaffolds or microcarriers. As used herein, the term “microcarrier” refers to a support matrix allowing for adherence / attachment, maturation, differentiation, and proliferation of cells in a culture, with at least one of it dimensions being in the micrometer range. In some aspects, the microcarrier is for growth of adherent cells in a non-adherent container. In some aspects, the microcarrier is for growth in a bioreactor. In some aspects, the non-adherent container is a bioreactor. As used herein, growth while adhered to a microcarrier is not anchorage- independent growth, as the cell is anchored to the microcarrier. In some aspects, the microcarriers as disclosed herein are edible microcarriers. As used herein, the term “scaffold” refers to a structure comprising a material that provides a surface suitable for adherence / attachment, maturation, differentiation, and proliferation of cells. A scaffold may further provide mechanical stability and support. A scaffold may be in a particular shape or form to influence or delimit a three-dimensional shape or form assumed by a population of proliferating cells. In some aspects, a scaffold of the invention is three-dimensional. In some aspects, the scaffold may comprise microcarriers as disclosed herein. In some aspects, the microcarriers, scaffolds or a combination thereof can be used for production of cell culture based cultured meat products. In some aspects, the microcarriers or scaffolds can be suspended in the cryopreservation media as disclosed herein and frozen.
[0035] In some aspects, the current disclosure also encompasses the use of the disclosed compositions for cryopreserving products manufactured using cellular agriculture techniques. In some aspects, these products may be in the form of tissue mass, organs, organoids, cellular biomass, cultured meat, and processed cultured meat products. In some aspects, the cultured meat for cryopreservation has substantially the same composition with respect to percent proteins, fat, carbohydrates and the like, such as beef, veal, pork, chicken, or fish. In some aspects, the cultured meat comprises a plurality of layers, wherein each layer comprises non- human myocytes and non-human endothelial cells. In various aspects, the cultured meat comprises a plurality of layers, wherein each layer comprises myocytes, and may include one or more of endothelial cells, adipose cells, and / or fibroblasts, wherein the cells are derived from sources including, but not limited to, mammals, birds, reptiles, fish, crustaceans, mollusks, and cephalopods, or combinations thereof. In some aspects, the myocytes are aligned relative to each other. In further aspects, the myocytes are aligned relative to a layer of the meat. In some aspects, the cultured meat is suitable for human consumption. In other aspects, the cultured meat is suitable for non-human animal consumption. In still other aspects, the cultured meat is suitable for both human and non-human animal consumption. In some aspects, the cultured meat is further 10 95004041.1Attorney Docket No.121430-791898 processed to make food products for example, cuts, fillets, mince, meat balls, sausages and comprise the compositions as disclosed herein for cryopreservation. In some aspects, the compositions do not need to be removed prior to consumption. In some aspects, these compositions may be removed prior to consumption.
[0036] In some aspects, any freezing method or technology can be used for freezing samples in the disclosed cryopreservation media. Methods of freezing and thawing cultures are well known in the art. In some aspects, samples can be frozen using liquid nitrogen, dry ice, ethanol dry ice mix or any other suitable method. In some aspects, the temperature of the culture may be brought down gradually. In some aspects, the culture may be frozen using ultrarapid freezing technologies. In some aspects, the sample can be frozen and stored at a temperature range of about −20° C to −196° C. In some aspects, the sample is frozen and stored at a temperature range of about −20° C to about −40° C, or about −40° C to about −60° C, or about −60° C to about −80° C, or about −80° C to about −100° C, or about −100° C to about −120° C, or about −120° C to about −140° C. or about −140° C to about −160° C, or about −160° C to about −180° C, or about −180° C to about −200° C.
[0037] In some aspects, the cryopreservation methods as disclosed herein enables the revival of at least 50% and preferably 70% or more of live cells in the sample, wherein the sample may be cells, cell lines, tissue mass, organs, organoids, cellular biomass, cultured meat, and processed cultured meat products. III. Terminology
[0038] The phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting. For example, the use of a singular term, such as, “a” is not intended as limiting of the number of items. Also, the use of relational terms such as, but not limited to, “top,” “bottom,” “left,” “right,” “upper,” “lower,” “down,” “up,” and “side,” are used in the description for clarity in specific reference to the figures and are not intended to limit the scope of the present inventive concept or the appended claims.
[0039] Further, as the present inventive concept is susceptible to aspects of many different forms, it is intended that the present disclosure be considered as an example of the principles of the present inventive concept and not intended to limit the present inventive concept to the specific aspects shown and described. Any one of the features of the present inventive concept may be used separately or in combination with any other feature. References to the terms “aspect,” “aspects,” and / or the like in the description mean that the feature and / or features being referred 11 95004041.1Attorney Docket No.121430-791898 to are included in, at least, one aspect of the description. Separate references to the terms “aspect,” “aspects,” and / or the like in the description do not necessarily refer to the same aspect and are also not mutually exclusive unless so stated and / or except as will be readily apparent to those skilled in the art from the description. For example, a feature, structure, process, step, action, or the like described in one aspect may also be included in other aspects but is not necessarily included. Thus, the present inventive concept may include a variety of combinations and / or integrations of the aspects described herein. Additionally, all aspects of the present disclosure, as described herein, are not essential for its practice. Likewise, other systems, methods, features, and advantages of the present inventive concept will be, or become, apparent to one with skill in the art upon examination of the figures and the description. It is intended that all such additional systems, methods, features, and advantages be included within this description, be within the scope of the present inventive concept, and be encompassed by the claims.
[0040] Any term of degree such as, but not limited to, “substantially” as used in the description and the appended claims, should be understood to include an exact, or a similar, but not exact configuration. For example, “a substantially planar surface” means having an exact planar surface or a similar, but not exact planar surface. Similarly, the terms “about” or “approximately,” as used in the description and the appended claims, should be understood to include the recited values or a value that is three times greater or one third of the recited values. For example, about 3 mm includes all values from 1 mm to 9 mm, and approximately 50 degrees includes all values from 16.6 degrees to 150 degrees. For example, they can refer to less than or equal to ± 5%, such as less than or equal to ± 2%, such as less than or equal to ± 1%, such as less than or equal to ± 0.5%, such as less than or equal to ± 0.2%, such as less than or equal to ± 0.1%, such as less than or equal to ± 0.05%.
[0041] The terms "comprising," "including" and "having" are used interchangeably in this disclosure. The terms "comprising," "including" and "having" mean to include, but not necessarily be limited to the things so described.
[0042] Lastly, the terms “or” and “and / or,” as used herein, are to be interpreted as inclusive or meaning any one or any combination. Therefore, “A, B or C” or “A, B and / or C” mean any of the following: “A,” “B” or “C”; “A and B”; “A and C”; “B and C”; “A, B and C.” An exception to this definition will occur only when a combination of elements, functions, steps or acts are in some way inherently mutually exclusive. 12 95004041.1Attorney Docket No.121430-791898 EXAMPLES
[0043] The following examples are included to demonstrate preferred aspects of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventor to function well in the practice of the present disclosure, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific aspects which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the present disclosure. EXAMPLE 1
[0044] Provided are some exemplary formulations: Formulations 1: ^ 20% Chicken egg yolk ^ 10% glycerin ^ DMEM / F12 culture media up to 100% Formulations 2: ^ 15% Chicken egg yolk ^ 10% glycerin ^ 1% dextrose ^ 1% sodium chloride ^ Water up 100% Formulation 3: ^ 20% Chicken egg yolk ^ 5% PVP ^ DMEM culture media up to 100%
[0045] These exemplary formulations were tested against three commercially available formulations, provided here as comparative formulations 4-6. 13 95004041.1Attorney Docket No.121430-791898 Comparative Formulation 4: ^ 10% DMSO ^ 10% glycerin ^ DMEM culture media up to 100% Comparative Formulation 5: ^ 10% glycerin ^ DMEM culture media up to 100% Comparative Formulation 6: ^ 10% Fetal Bovine Serum ^ DMEM culture media up to 100%
[0046] To test the formulations, chicken fibroblasts were cultured in cell culture flask. After, trypsinization and detaching the cells from flask, they were thoroughly washed with buffer phosphate and centrifuged to obtain a cell pellet. The pellets were resuspended in above mentioned formulation and transferred to cryotubes. The samples were then frozen in a deep freezer (-80 ºC) using freezing container for gradual cool down at the rate of 1 ºC per minute. The samples were stored in -80 ºC for 1 day. The samples were thawed and cell viability was studied using live dead immunostaining assay. The results with 50% and preferably 70% or more viable cells were considered successful. The viability data for the above recited formulations 1-3 and the comparative formulations 4-6 are listed in following table: Table 1: Cell viability after cryopreservation Formulation Average Viability (%) 1 92 2 87 3 91 4 92 5 53 6 20 14 95004041.1Attorney Docket No.121430-791898
[0047] As seen from Table 1, all the recited new formulations were found to support high cell viability post cryopreservation and thawing. 15 95004041.1
Claims
Attorney Docket No.121430-791898 CLAIMS 1. A cryopreservation medium for use in cellular agriculture applications, the media comprising egg yolk and at least one additional edible cryoprotectant.
2. The cryopreservation medium of claim 1, wherein the at least one additional edible cryoprotectant is selected from glycerin, sorbitol, trehalose, polyvinylpyrrolidone(PVP), betaine, carboxylated poly-l-lysine, glucose, dextran, proline, peptides, sucrose, or any combination thereof.
3. The cryopreservation medium of claim 1, wherein the media does not contain DMSO.
4. The cryopreservation medium of claim 1, wherein the medium comprises about 5% to about 30% of egg yolk.
5. The cryopreservation medium of claim 4, wherein the medium comprises about 20% of egg yolk.
6. The cryopreservation medium of claim 2, wherein the medium comprises about 5% to about 25% glycerin.
7. The cryopreservation medium of claim 6, wherein the medium comprises about 10% glycerin.
8. The cryopreservation medium of any one of claims 1-7, wherein the egg yolk is obtained from an oviparous animal selected from a fish, amphibian, reptile, or any combination thereof.
9. The cryopreservation medium of claim 8, wherein the egg yolk is from an avian animal.
10. The cryopreservation medium of claim 9, wherein the avian animal is a chicken, ostrich, quail, partridge, or turkey.
11. The cryopreservation medium of any one of claim 1-10, wherein the medium further comprises one or more of a salt, a sugar, a fat, a basal medium, a growth factors, amino acids, vitamins, minerals, edible surfactants, preservatives, antibiotics, pectin, alginate, agarose, elastin, chitin, chitosan, fibrin, fibrinogen, polysaccharides, alginates, collagen, 16 95004041.1Attorney Docket No.121430-791898 gelatin, poly(amino acids), peptides, polypeptides, fibers, buffering agents or any combinations thereof.
12. The cryopreservation medium of any one of claim 1-11, for preservation of at least a non- human cell.
13. The cryopreservation medium of claim 12, for preservation of non-human animal cells, non-human cell lines, non-human cell population, non-human cell cultures, non-human tissue, non-human organ or non-human cellular biomass.
14. The cryopreservation medium of claim 12, wherein the non-human animal cell is a fibroblast, a myoblast, an adipocyte, a stem cell, an endothelial cell, or a mesodermal cell or any combination thereof.
15. The cryopreservation medium of claim 13, wherein the non-human cell cultures, or non- human cellular biomass is preserved in a bioreactor container.
16. The cryopreservation medium of claim 1, wherein the temperature range of the cryopreservation is −20 °C. to −196 °C.
17. The cryopreservation medium of claim 1, wherein the medium is a ready-to-use medium.
18. The cryopreservation medium of claim 1, wherein the medium is a concentrate.
19. A method of cryopreservation for cellular agriculture applications, the method comprising contacting at least one non-human animal cell with a medium comprising egg yolk and at least one additional edible cryoprotectant.
20. A method of cryopreservation for cellular agriculture applications, the method comprising contacting at least one non-human animal cell with the cryopreservation medium of any one of claims 1-18.
21. The method of claim 19 or 20, wherein the non-human animal cell is a fibroblast, a myoblast, an adipocyte, a stem cell, an endothelial cell, or a mesodermal cell or any combination thereof. 17 95004041.1Attorney Docket No.121430-791898 22. The method of claim 19 or 20, wherein the at least one non-human cell is part of a non- human cell population, non-human cell cultures, non-human tissue, non-human organ, non-human cellular biomass, or non-human cell grown on microcarrier and / or scaffolds.
23. The method of any one of claims 19-22, wherein the non-human cell is in a dish, tube, plate, jar or a bioreactor.
24. The method of any one of claims 19-23, wherein the recovery survival rate of the non- human cell is at least about 50% to about 70%, or more.
25. The method of any one of claim 19-24, wherein the non-human cells are suspended in the cryopreservation medium at a concentration that 1×102to 1×109non-human cells / mL of said cell cryopreservation protective solution.
26. The method according to claim 13, wherein the temperature range of the cryopreservation is −20 °C. to −196 °C.
27. The method of claim 19 or 20, wherein the cryopreservation is ultrarapid cryopreservation.
28. The method of claim 19 or 20, wherein the cryopreservation is gradual cryopreservation.
29. A method of cellular agriculture, the method comprising; (a) growing non-human animal cells in a bioreactor container; (b) adding a cryopreservation medium of any one of claims 1-18 to the bioreactor container; (c) freezing the non-human animal cells in the bioreactor container.
30. The method of claim 29; wherein step (c) is an ultrarapid freezing.
31. The method of claim 29, wherein the non-human animal cells are grown to a density of about 1×102to 1×109non-human cells / mL.
32. The method of any one of claims 29-30, wherein the recovery survival rate of the non- human animal cells is at least about 50% to about 70%, or more.
33. The method of claim 29, further comprising thawing the non-human animal cells in the bioreactor container. 18 95004041.1Attorney Docket No.121430-791898 34. The method of claim 33, further comprising resuming the growth of the non-human cells.
35. The method of claim 33 or 34, further comprising concentrating the cells for production of a cultured meat product.
36. The method of claim 29, for use of production of cultured meat products, recombinant proteins, or structured animal products. 19 95004041.1
Citation Information
Patent Citations
Cryopreservation of sperm
US20020131957A1
System and Substances for Cryopreservation of Viable Cells
US20150037783A1
Duck egg yolk Anti-freezing agent for cryopreservation of donkey semen and preparation method thereof
WO2014089924A1
